Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea

Blood (2024) 144 (21): 2211–2222.

https://doi.org/10.1182/blood.2024024944

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

David Sharon, Fengjiao Dunbar, Paul Jung, Xifeng Wang, Xiaotong Li, Christine Mantis, Orlando F. Bueno, Cyrille Touzeau, Philippe Moreau, Simon J Harrison, Luciano J. Costa, Jonathan L. Kaufman, Nizar J. Bahlis, Shaji K Kumar, Jeremy A. Ross, P.K. Epling-Burnette

Blood (2022) 140 (Supplement 1): 4242–4244.

https://doi.org/10.1182/blood-2022-160195

Published: 2022

Journal Articles

Genomic Landscape of t(11;14) in Multiple Myeloma

Jeremy A. Ross, Herve Avet-Loiseau, Xiaotong Li, Raphaele Thiebaut-Millot, Carlos Hader

Blood (2022) 140 (Supplement 1): 10092–10093.

https://doi.org/10.1182/blood-2022-167167

Published: 2022

Journal Articles

PTBP1 Regulates Alternative Splicing of Apoptotic Protein: Implications in CLL and Ibrutinib Resistance

Huayuan Zhu, Xiaotong Li, Xinqi Zheng, Juejin Wang, Hanning Tang, Wei Xu, MD PhD, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 1290.

https://doi.org/10.1182/blood-2019-126945

Published: 2019

Journal Articles

Protein Replacement by Receptor-Mediated Endocytosis Corrects the Sensitivity of Fanconi Anemia Group C Cells to Mitomycin C

Hagop Youssoufian, Frank A.E. Kruyt, Xiaotong Li

Blood (1999) 93 (1): 363–369.

https://doi.org/10.1182/blood.V93.1.363

Published: 1999

NARROW

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

Genomic Landscape of t(11;14) in Multiple Myeloma

PTBP1 Regulates Alternative Splicing of Apoptotic Protein: Implications in CLL and Ibrutinib Resistance

Protein Replacement by Receptor-Mediated Endocytosis Corrects the Sensitivity of Fanconi Anemia Group C Cells to Mitomycin C

Email alerts

ASH Publications

American Society of Hematology

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

Genomic Landscape of t(11;14) in Multiple Myeloma

PTBP1 Regulates Alternative Splicing of Apoptotic Protein: Implications in CLL and Ibrutinib Resistance

Protein Replacement by Receptor-Mediated Endocytosis Corrects the Sensitivity of Fanconi Anemia Group C Cells to Mitomycin C

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only